Risk factor
Very high price volatility
Profitability factor
Very strong margins and returns
About
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the United States, Switzerland, and other global markets. The company's flagship drug, SCENESSE, serves as a systemic photoprotective treatment intended to prevent phototoxicity in adult patients diagnosed with erythropoietic protoporphyria (EPP). Clinuvel's development pipeline includes CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which promotes prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Additionally, Clinuvel Pharmaceuticals has partnered with HK Winhealth Pharma Group Co. Limited for a named patient program in the People's Republic of China, enabling the treatment of EPP patients with SCENESSE. Founded in 1987, the company's corporate headquarters are situated in Melbourne, Australia.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is underpriced on P/E, of fair value on EV/EBITDA, underv
Target Price
The average target price of CUV.AX is 22.1 and suggests 131% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc